Vitamin D as a therapy for colitis: A systematic review

Journal of Crohn's and Colitis

Volumn 6, Issue 4, 2012, Pages 405-411

  Nicholson, Imogen ^a   Dalzell, A Mark ^a   El Matary, Wael ^b,c  

^a ALDER HEY CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF MANITOBA   (Canada)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Colitis; Crohn's; Inflammatory bowel disease; Vitamin d

Indexed keywords

ALFACALCIDOL; CALCITRIOL; CALCIUM; COLECALCIFEROL; PLACEBO; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D DERIVATIVE; ZK 156979;

COCHRANE LIBRARY; COLITIS; DISEASE ACTIVITY; DRUG EFFECT; DRUG MEGADOSE; HUMAN; MEDLINE; NONHUMAN; PRIORITY JOURNAL; RELAPSE; REVIEW; SYSTEMATIC REVIEW; VITAMIN SUPPLEMENTATION;

ANIMALS; COLITIS; HUMANS; INFLAMMATORY BOWEL DISEASES; VITAMIN D; VITAMINS;

EID: 84860167143     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2012.01.007     Document Type: Review

References (34)

1. Bhalla A.K., Amento E.P., Clemens T.L., Holick M.F., Krane S.M. Specific high-affinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation. J Clin Endocrinol Metab 1983, 57:1308-1310.
2. Provvedini D.M., Tsoukas C.D., Deftos L.J., Manolagas S.C. 1,25-dihydroxyvitamin D3 receptors in human leukocytes. Science 1983, 221:1181-1183.
3. Cantorna M.T. Vitamin D and its role in immunology: multiple sclerosis, and inflammatory bowel disease. Prog Biophys Mol Biol 2006, 92:60-64.
4. Yang S., Smith C., Prahl J.M., Luo X., DeLuca H.F. Vitamin D deficiency suppresses cell-mediated immunity in vivo. Arch Biochem Biophys 1993, 303:98-106.
5. Yang S., Smith C., DeLuca H.F. 1 alpha, 25-Dihydroxyvitamin D3 and 19-nor-1 alpha, 25-dihydroxyvitamin D2 suppress immunoglobulin production and thymic lymphocyte proliferation in vivo. Biochim Biophys Acta 1993, 1158:279-286.
6. Holick M.F. Vitamin D: a millenium perspective. J Cell Biochem 2003, 88(2):296-307.
7. Webb A.R., Kline L., Holick M.F. Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J Clin Endocrinol Metab 1988, 67:373-378.
8. Levin A.D., Wadhera V., Leach S.T., Woodhead H.J., Lemberg D.A., Mendoza-Cruz A.C., et al. Vitamin D deficiency in children with inflammatory bowel disease. Dig Dis Sci 2011, 56:830-836.
9. Lim W.C., Hanauer S.B., Li Y.C. Mechanisms of disease: vitamin D and inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol 2005, 2:308-315.
10. Ardizzone S., Cassinotti A., Bevilacqua M., Clerici M., Porro G.B. Vitamin D and inflammatory bowel disease. Vitam Horm 2011, 86:367-377.
11. Monteleone G., Fina D., Caruso R., Pallone F. New mediators of immunity and inflammation in inflammatory bowel disease. Curr Opin Gastroenterol 2006, 22:361-364.
12. Namgung R., Mimouni F., Campaigne B.N., Ho M.L., Tsang R.C. Low bone mineral content in summer-born compared with winter-born infants. J Pediatr Gastroenterol Nutr 1992, 15:285-288.
13. Namgung R., Tsang R.C., Specker B.L., Sierra R.I., Ho M.L. Low bone mineral content and high serum osteocalcin and 1,25-dihydroxyvitamin D in summer- versus winter-born newborn infants: an early fetal effect?. J Pediatr Gastroenterol Nutr 1994, 19:220-227.
14. Rucker D., Allan J.A., Fick G.H., Hanley D.A. Vitamin D insufficiency in a population of healthy western Canadians. CMAJ 2002, 166:1517-1524.
15. Ulitsky A., Ananthakrishnan A.N., Naik A., Skaros S., Zadvornova Y., Binion D.G., et al. Vitamin D deficiency in patients with inflammatory bowel disease: association with disease activity and quality of life. JPEN J Parenter Enteral Nutr 2011, 35:308-316.
16. Gallo R.L., Lai Y.P. AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. Trends Immunol 2009, 30:131-141.
17. Hypponen E., Laara E., Reunanen A., Jarvelin M.R., Virtanen S.M. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 2001, 358:1500-1503.
18. Shine on Scotland campaign Multiple Sclerosis Society Scotland, Article, 24 April 2011, (accessed 5 July 2011). http://www.mssocietyscotland.org.uk/news_and_whats_on/news_whats_on/shine_scot.html.
19. Munger K.L., O'Reilly E., Ascherio A. Vitamin D intake and incidence of multiple sclerosis - reply from the authors. Neurology 2004, 63:939.
20. Andjelkovic Z., Vojinovic J., Pejnovic N., Popovic M., Dujic A., Mitrovic D., et al. Disease modifying and immunomodulatory effects of high dose 1 alpha (OH) D3 in rheumatoid arthritis patients. Clin Exp Rheumatol 1999, 17:453-456.
21. Jadad A.R., Moore R.A., Carroll D. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17:1-12.
22. Higgins J.P.T., Altman D.G. Chapter 8: assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008) 2008, The Cochrane Collaboration. J. Higgins, S. Green (Eds.).
23. Cantorna M.T., Munsick C., Bemiss C., Mahon B.D. 1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J Nutr 2000, 130:2648-2652.
24. Daniel C., Radeke H.H., Sartory N.A., Zahn N., Zuegel U., Steinmeyer A., et al. The new low calcemic vitamin D analog 22-ene-25-oxa-vitamin D prominently ameliorates T helper cell type 1-mediated colitis in mice. J Pharmacol Exp Ther 2006, 319:622-631.
25. Miheller P., Muzes G., Hritz I., Lakatos G., Pregun I., Lakatos P.L., et al. Comparison of the effects of 1,25 dihydroxyvitamin D and 25 hydroxyvitamin D on bone pathology and disease activity in Crohn's disease patients. Inflamm Bowel Dis 2009, 15:1656-1662.
26. Jorgensen S.P., Agnholt J., Glerup H., Lyhne S., Villadsen G.E., Hvas C.L., et al. Clinical trial: vitamin D3 treatment in Crohn's disease - a randomized double-blind placebo-controlled study. Aliment Pharmacol Ther 2010, 32:377-383.
27. Harries A.D., Brown R., Heatley R.V., Williams L.A., Woodhead S., Rhodes J. Vitamin D status in Crohn's disease: association with nutrition and disease activity. Gut 2007, 26:1197-1203.
28. Ginanjar E., Sumariyono, Setiati S., Setiyohadi B. Vitamin D and autoimmune disease. Acta Medica Indonesiana 1985, 39:133-141.
29. Froicu M., Weaver V., Wynn T.A., McDowell M.A., Welsh J.E., Cantorna M.T. A crucial role for the vitamin D receptor in experimental inflammatory bowel diseases. Mol Endocrinol 2003, 17:2386-2392.
30. El-Matary W., Sikora S., Spady D. Bone mineral density, vitamin D, and disease activity in children newly diagnosed with inflammatory bowel disease. Dig Dis Sci 2011, 56:825-829.
31. Gilman J., Shanahan F., Cashman K.D. Determinants of vitamin D status in adult Crohn's disease patients, with particular emphasis on supplemental vitamin D use. Eur J Clin Nutr 2006, 60:889-896.
32. Leslie W.D., Miller N., Rogala L., Bernstien C.N. Vitamin D status and bone density in recently diagnosed inflammatory bowel disease: the Manitoba IBD Cohort Study. Am J Gastroenterol 2008, 103:1451-1459.
33. Stio M., Bonanomi A.G., d'Albasio G., Treves C. Suppressive effect of 1,25-dihydroxyvitamin D3 and its analogues EB 1089 and KH 1060 on T lymphocyte proliferation in active ulcerative colitis. Biochem Pharmacol 2001, 61:365-371.
34. Cantorna M. Mechanisms underlying the effect of vitamin D on the immune system. Proc Nutr Soc 2010, 69:286-289.